论文信息 - Treatment of depression as part of end-of-life care

Treatment of depression as part of end-of-life care

We present a case report of a severe treatment resistant major depressive episode in a patient with advanced cancer and limited life expectancy which resolved completely within 10 days of commencing combination therapy involving mirtazepine and paroxetine. Aggressive treatment of clinical depression even in the context of short life expectancy (that is, a short number of weeks) can dramatically reduce patient and family distress and improve quality of life.

M. Murphy | B. Hannon | P. Fitzgerald

[1] A. Payne,et al. Sensitivity and specificity of a two-question screening tool for depression in a specialist palliative care unit , 2007, Palliative medicine.

[2] M. Lloyd-Williams,et al. How do palliative medicine physicians assess and manage depression , 2003, Palliative medicine.

[3] M. Lloyd-Williams,et al. Which depression screening tools should be used in palliative care? , 2003, Palliative medicine.

[4] M. Hotopf,et al. Depression in advanced disease: a systematic review Part 1. Prevalence and case finding , 2002, Palliative medicine.

[5] C. Benedetti,et al. Mirtazepine: Heir apparent to amitriptyline? , 2001, The American journal of hospice & palliative care.

[6] J. Kent. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression , 2000, The Lancet.

[7] H. Chochinov,et al. "Are you depressed?" Screening for depression in the terminally ill. , 1997, The American journal of psychiatry.

[8] P. Maguire,et al. Antidepressant medications in cancer patients , 1994 .

[9] J. Amsterdam,et al. Treatment-resistant depression in the age of serotonin: evolving strategies , 2000 .

[10] J. Shuster,et al. Psychiatric aspects of excellent end-of-life care. Ad Hoc Committee on End-of-Life Care. The Academy of Psychosomatic Medicine. , 1999, Psychosomatics.

[11] T. Boer. The pharmacologic profile of mirtazapine. , 1996 .